1. An agent for treatment of arthritic disease containing a complex of hyaluronic acid and zinc. 2. An agent for treatment of arthritic disease as set forth in claim 1 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 100 kD to about 2,000 kD. 3. An agent for treatment of arthritic disease as set forth in claim 2 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 1,000 kD. 4. An agent for treatment of arthritic disease as set forth in any of claims 1 through 3 wherein the weight ratio of hyaluronic acid and zinc is from 5:1 to 20:1. 5. An agent for treatment of arthritic disease as set forth in claim 4 wherein the weight ratio of hyaluronic acid and zinc is about 10:1. 6. An agent for treatment of arthritic disease as set forth in any of claims 1 through 5 wherein said arthritic disease is rheumatoid arthritis, osteoarthritis, hydrarthrosis or rapidly destructive malum coxae. 7. An agent for treatment of arthritic disease as set forth in claim 6 wherein said arthritic disease is rheumatoid arthritis. 8. A matrix metalloproteinase MMP-9 suppresser containing a complex of hyaluronic acid and zinc. 9. A matrix metalloproteinase MMP-9 suppresser as set forth in claim 8 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 100 kD to about 2,000 kD. 10. A matrix metalloproteinase MMP-9 suppresser as set forth in claim 9 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 1,000 kD. 11. A matrix metalloproteinase MMP-9 suppresser as set forth in any of claims 8 through 10 wherein the weight ratio of hyaluronic acid and zinc is from 5:1 to 20:1. 12. A matrix metalloproteinase MMP-9 suppresser as set forth in claim 11 wherein the weight ratio of hyaluronic acid and zinc is about 10:1. 13. A matrix metalloproteinase MMP-9 suppresser as set forth in any of claims 8 through 12 wherein said matrix metalloproteinase MMP-9 suppresser is an agent for treatment of insulin-dependent proliferative diabetic retinopathy or an inhibitor of malignant tumor invasion or metastasis. 14. A use of a complex of hyaluronic acid and zinc for the production of an agent for treatment of arthritic disease. 15. A use as set forth in claim 14 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 100 kD to about 2,000 kD. 16. A use as set forth in claim 15 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 1,000 kD. 17. A use as set forth in any of claims 14 through 16 wherein the weight ratio of hyaluronic acid and zinc is from 5:1 to 20:1. 18. A use as set forth in claim 17 wherein the weight ratio of hyaluronic acid and zinc is about 10:1. 19. A use as set forth in any of claims 14 through 18 wherein said arthritic disease is rheumatoid arthritis, osteoarthritis, hydrarthrosis or rapidly destructive malum coxae. 20. A use as set forth in claim 19 wherein said arthritic disease is rheumatoid arthritis. 21. A use of a complex of hyaluronic acid and zinc for the production of matrix metalloproteinase MMP-9 suppresser. 22. A use as set forth in claim 21 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 100 kD to about 2,000 kD. 23. A use as set forth in claim 22 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 1,000 kD. 24. A use as set forth in any of claims 21 through 23 wherein the weight ratio of hyaluronic acid and zinc is from 5:1 to 20:1. 25. A use as set forth in claim 24 wherein the weight ratio of hyaluronic acid and zinc is about 10:1. 26. A use as set forth in any of claims 21 through 25 wherein said matrix metalloproteinase MMP-9 suppresser is an agent for treatment of insulin-dependent proliferative diabetic retinopathy or an inhibitor of malignant tumor invasion or metastasis. 27. A treatment method for arthritic disease comprising administration of a complex of hyaluronic acid and zinc to a patient having an arthritic disease. 28. A treatment method as set forth in claim 27 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 100 kD to about 2,000 kD. 29. A treatment method as set forth in claim 28 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 1,000 kD. 30. A treatment method as set forth in any of claims 27 through 29 wherein the weight ratio of hyaluronic acid and zinc is from 5:1 to 20:1. 31. A treatment method as set forth in claim 30 wherein the weight ratio of hyaluronic acid and zinc is about 10:1. 32. A treatment method as set forth in any of claims 27 through 30 wherein said arthritic disease is rheumatoid arthritis, osteoarthritis, hydrarthrosis or rapidly destructive malum coxae. 33. A treatment method as set forth in claim 32 wherein said arthritic disease is rheumatoid arthritis. 34. A method of suppressing accelerated production of matrix metalloproteinase MMP-9 comprising administration of a complex of hyaluronic acid and zinc to a patient having accelerated production of matrix metalloproteinase MMP-9. 35. A method as set forth in claim 34 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 100 kD to about 2,000 kD. 36. A method as set forth in claim 35 wherein said complex of hyaluronic acid and zinc has a molecular weight of about 1,000 kD. 37. A method as set forth in any of claims 34 through 36 wherein the weight ratio of hyaluronic acid and zinc is from 5:1 to 20:1. 38. A method as set forth in claim 37 wherein the weight ratio of hyaluronic acid and zinc is about 10:1. 39. A method as set forth in any of claims 34 through 38 wherein said matrix metalloproteinase MMP-9 suppresser is an agent for treatment of insulin-dependent proliferative diabetic retinopathy or an inhibitor of malignant tumor invasion or metastasis.